Merck KGaA, Darmstadt, Germany: Neoplasm Metastasis trials
The registry lists 21 Neoplasm Metastasis studies with Merck KGaA, Darmstadt, Germany as lead sponsor. 0 are open to participants now and 11 have results posted.
Phase 1 13Phase 2 5Phase 3 1No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- First in Human Study of M1069 in Advanced Solid TumorsTerminatedNCT05198349Phase 1Results posted
- First-in-Human Study of MS201408-0005A as Single Agent and in CombinationsTerminatedNCT03306420Phase 1Results posted
- Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)CompletedNCT02625610Phase 3Results posted
- MSB0011359C (M7824) in Metastatic or Locally Advanced Solid TumorsCompletedNCT02517398Phase 1Results posted
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedNCT01390818Phase 1Results posted
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerCompletedNCT01016483Phase 1/2Results posted
- EMD 525797 in Colorectal and Ovarian Cancer Patients With Liver MetastasesCompletedNCT00848510Phase 1Results posted
- Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedNCT00705016Phase 1/2Results posted
- Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast CancerCompletedNCT00463788Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.CompletedNCT00439517Phase 2Results posted
- Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)CompletedNCT00125034Phase 2Results posted
- Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)CompletedNCT05396833Phase 1
- Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)CompletedNCT04170153Phase 1
- A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical PracticeCompletedNCT01460745
- EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and NeckTerminatedNCT01360827Phase 1
- Prevalence of the Mutational Status of V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) in Metastatic Colorectal Cancer (mCRC) in Argentine PatientsCompletedNCT01082757
- A Korean Post-marketing Surveillance Study on Erbitux® in Patients With Metastatic Colorectal Cancer Refractory to Irinotecan-containing TreatmentCompletedNCT01082315
- An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing TreatmentTerminatedNCT01074333
- EMD 521873 in Advanced Solid Tumors, MTD FindingCompletedNCT01032681Phase 1
- Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal CancerTerminatedNCT00719199Phase 1
- Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLCCompletedNCT00633529Phase 1